Another cancer deal...
https://www.reuters.com/article/americasMergersNews/idUSLS55200620090528
Exelixis... for two PI compounds!!!
Under the agreement, Sanofi will have an exclusive worldwidelicense to XL147 and XL765, which are in Phase I clinicaltrials. The companies also agreed on an exclusive partnershipfor the discovery of inhibitors of phosphoinositide-3 kinase(PI3K) for the management of solid malignancies.
I still laugh at how pepmoron was posting saying that TLN is an early stage company... that no one signs deals with "early stage companies"... what a f.... moron you are pepmoron...
This puts even more pressure on TLN bidders. Give price support for a partnership deal. Give a price support to a takeover deal.
Shopping season is heating up for oncology plays...
It is now virtually impossible for TLN not to be taken over. Inferior compounds are flying away at a hefty price...